Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes

Clin Immunol. 2010 Aug;136(2):170-3. doi: 10.1016/j.clim.2010.04.009. Epub 2010 May 18.


Objective: Interleukin 1-beta (IL-1beta) is a major inflammatory cytokine. Blockade of the IL-1beta pathway is therapeutically efficacious in type 2 diabetes, but the mechanistic effects on the immune system are incompletely understood.

Research design: We administered an IL-1 receptor antagonist, anakinra, to 7 type 1 diabetes patients in order to investigate the immunologic and metabolic effects of this drug. Mechanistic assays were performed before and after drug administration.

Results: A novel signature was observed, with reduced serum interleukin 8 (IL-8) levels and reduced CD11b integrin expression on monocytes associated with increased CXCR1 expression.

Conclusions: This set of linked phenotypes suggests that blockade of the IL-1beta pathway results in the reduced ability of mononuclear cells to traffic to sites of inflammation. Mechanistic studies from large scale trials using IL-1 blockade in type 1 diabetes should focus on changes in monocyte trafficking and the IL-8 pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • CD11b Antigen / genetics
  • CD11b Antigen / metabolism*
  • Diabetes Mellitus, Type 1 / metabolism*
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Interleukin 1 Receptor Antagonist Protein / pharmacology*
  • Interleukin-1beta / antagonists & inhibitors*
  • Interleukin-8 / metabolism*
  • Middle Aged
  • Monocytes / drug effects
  • Monocytes / metabolism*
  • Young Adult


  • CD11b Antigen
  • Hypoglycemic Agents
  • ITGAM protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1beta
  • Interleukin-8